Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 49 entries
Sorted by: Best Match Show Resources per page
GCAP1, Rab6, and HSP27: Novel Autoantibody Targets in Cancer-Associated Retinopathy and Autoimmune Retinopathy.

Translational vision science & technology

Yang S, Dizhoor A, Wilson DJ, Adamus G.
PMID: 27152249
Transl Vis Sci Technol. 2016 May 02;5(3):1. doi: 10.1167/tvst.5.3.1. eCollection 2016 May.

PURPOSE: Autoantibodies (AAbs) with different retinal specificities were reported in cancer-associated retinopathy (CAR) and autoimmune retinopathy (AR). The goal was to identify the small retinal proteins of apparent molecular mass of 23-kDa often recognized by patients' AAbs.METHODS: Sera specific...

Cite
Yang S, Dizhoor A, Wilson DJ, et al. GCAP1, Rab6, and HSP27: Novel Autoantibody Targets in Cancer-Associated Retinopathy and Autoimmune Retinopathy. Transl Vis Sci Technol. 2016;5(3):1doi: 10.1167/tvst.5.3.1.
Yang, S., Dizhoor, A., Wilson, D. J., & Adamus, G. (2016). GCAP1, Rab6, and HSP27: Novel Autoantibody Targets in Cancer-Associated Retinopathy and Autoimmune Retinopathy. Translational vision science & technology, 5(3), 1. https://doi.org/10.1167/tvst.5.3.1
Yang, Sufang, et al. "GCAP1, Rab6, and HSP27: Novel Autoantibody Targets in Cancer-Associated Retinopathy and Autoimmune Retinopathy." Translational vision science & technology vol. 5,3 (2016): 1. doi: https://doi.org/10.1167/tvst.5.3.1
Yang S, Dizhoor A, Wilson DJ, Adamus G. GCAP1, Rab6, and HSP27: Novel Autoantibody Targets in Cancer-Associated Retinopathy and Autoimmune Retinopathy. Transl Vis Sci Technol. 2016 May 02;5(3):1. doi: 10.1167/tvst.5.3.1. eCollection 2016 May. PMID: 27152249; PMCID: PMC4855477.
Copy Download .nbib Format: NLM
Data detailing the platelet acetyl-lysine proteome.

Data in brief

Aslan JE, David LL, McCarty OJ.
PMID: 26904711
Data Brief. 2015 Oct 09;5:368-71. doi: 10.1016/j.dib.2015.09.020. eCollection 2015 Dec.

Here we detail proteomics data that describe the acetyl-lysine proteome of blood platelets (Aslan et al., 2015 [1]). An affinity purification - mass spectrometry (AP-MS) approach was used to identify proteins modified by Nε-lysine acetylation in quiescent, washed human...

Cite
Aslan JE, David LL, McCarty OJ. Data detailing the platelet acetyl-lysine proteome. Data Brief. 2015;5:368-71doi: 10.1016/j.dib.2015.09.020.
Aslan, J. E., David, L. L., & McCarty, O. J. (2015). Data detailing the platelet acetyl-lysine proteome. Data in brief, 5368-71. https://doi.org/10.1016/j.dib.2015.09.020
Aslan, Joseph E, et al. "Data detailing the platelet acetyl-lysine proteome." Data in brief vol. 5 (2015): 368-71. doi: https://doi.org/10.1016/j.dib.2015.09.020
Aslan JE, David LL, McCarty OJ. Data detailing the platelet acetyl-lysine proteome. Data Brief. 2015 Oct 09;5:368-71. doi: 10.1016/j.dib.2015.09.020. eCollection 2015 Dec. PMID: 26904711; PMCID: PMC4726637.
Copy Download .nbib Format: NLM
Development of coagulation factor probes for the identification of procoagulant circulating tumor cells.

Frontiers in oncology

Tormoen GW, Cianchetti FA, Bock PE, McCarty OJ.
PMID: 22973554
Front Oncol. 2012 Sep 06;2:110. doi: 10.3389/fonc.2012.00110. eCollection 2012.

Metastatic cancer is associated with a hypercoagulable state, and pathological venous thromboembolic disease is a significant source of morbidity and the second leading cause of death in patients with cancer. Here we aimed to develop a novel labeling strategy...

Cite
Tormoen GW, Cianchetti FA, Bock PE, et al. Development of coagulation factor probes for the identification of procoagulant circulating tumor cells. Front Oncol. 2012;2:110doi: 10.3389/fonc.2012.00110.
Tormoen, G. W., Cianchetti, F. A., Bock, P. E., & McCarty, O. J. (2012). Development of coagulation factor probes for the identification of procoagulant circulating tumor cells. Frontiers in oncology, 2110. https://doi.org/10.3389/fonc.2012.00110
Tormoen, Garth W, et al. "Development of coagulation factor probes for the identification of procoagulant circulating tumor cells." Frontiers in oncology vol. 2 (2012): 110. doi: https://doi.org/10.3389/fonc.2012.00110
Tormoen GW, Cianchetti FA, Bock PE, McCarty OJ. Development of coagulation factor probes for the identification of procoagulant circulating tumor cells. Front Oncol. 2012 Sep 06;2:110. doi: 10.3389/fonc.2012.00110. eCollection 2012. PMID: 22973554; PMCID: PMC3434442.
Copy Download .nbib Format: NLM
Increased Hemodynamic Load in Early Embryonic Stages Alters Myofibril and Mitochondrial Organization in the Myocardium.

Frontiers in physiology

Midgett M, López CS, David L, Maloyan A, Rugonyi S.
PMID: 28912723
Front Physiol. 2017 Aug 30;8:631. doi: 10.3389/fphys.2017.00631. eCollection 2017.

Normal blood flow is essential for proper heart formation during embryonic development, as abnormal hemodynamic load (blood pressure and shear stress) results in cardiac defects seen in congenital heart disease (CHD). However, the detrimental remodeling processes that relate altered...

Cite
Midgett M, López CS, David L, et al. Increased Hemodynamic Load in Early Embryonic Stages Alters Myofibril and Mitochondrial Organization in the Myocardium. Front Physiol. 2017;8:631doi: 10.3389/fphys.2017.00631.
Midgett, M., López, C. S., David, L., Maloyan, A., & Rugonyi, S. (2017). Increased Hemodynamic Load in Early Embryonic Stages Alters Myofibril and Mitochondrial Organization in the Myocardium. Frontiers in physiology, 8631. https://doi.org/10.3389/fphys.2017.00631
Midgett, Madeline, et al. "Increased Hemodynamic Load in Early Embryonic Stages Alters Myofibril and Mitochondrial Organization in the Myocardium." Frontiers in physiology vol. 8 (2017): 631. doi: https://doi.org/10.3389/fphys.2017.00631
Midgett M, López CS, David L, Maloyan A, Rugonyi S. Increased Hemodynamic Load in Early Embryonic Stages Alters Myofibril and Mitochondrial Organization in the Myocardium. Front Physiol. 2017 Aug 30;8:631. doi: 10.3389/fphys.2017.00631. eCollection 2017. PMID: 28912723; PMCID: PMC5582297.
Copy Download .nbib Format: NLM
Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations.

Cellular and molecular gastroenterology and hepatology

Smith NR, Swain JR, Davies PS, Gallagher AC, Parappilly MS, Beach CZ, Streeter PR, Williamson IA, Magness ST, Wong MH.
PMID: 29928673
Cell Mol Gastroenterol Hepatol. 2018 Mar 10;6(1):79-96. doi: 10.1016/j.jcmgh.2018.02.007. eCollection 2018.

BACKGROUND & AIMS: Continual renewal of the intestinal epithelium is dependent on active- and slow-cycling stem cells that are confined to the crypt base. Tight regulation of these stem cell populations maintains homeostasis by balancing proliferation and differentiation to...

Cite
Smith NR, Swain JR, Davies PS, et al. Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol. 2018;6(1):79-96doi: 10.1016/j.jcmgh.2018.02.007.
Smith, N. R., Swain, J. R., Davies, P. S., Gallagher, A. C., Parappilly, M. S., Beach, C. Z., Streeter, P. R., Williamson, I. A., Magness, S. T., & Wong, M. H. (2018). Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cellular and molecular gastroenterology and hepatology, 6(1), 79-96. https://doi.org/10.1016/j.jcmgh.2018.02.007
Smith, Nicholas R, et al. "Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations." Cellular and molecular gastroenterology and hepatology vol. 6,1 (2018): 79-96. doi: https://doi.org/10.1016/j.jcmgh.2018.02.007
Smith NR, Swain JR, Davies PS, Gallagher AC, Parappilly MS, Beach CZ, Streeter PR, Williamson IA, Magness ST, Wong MH. Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol. 2018 Mar 10;6(1):79-96. doi: 10.1016/j.jcmgh.2018.02.007. eCollection 2018. PMID: 29928673; PMCID: PMC6008251.
Copy Download .nbib Format: NLM
Examining the Protein Interactome and Subcellular Localization of RNase J2 Complexes in .

Frontiers in microbiology

Mu R, Shinde P, Zou Z, Kreth J, Merritt J.
PMID: 31620106
Front Microbiol. 2019 Sep 18;10:2150. doi: 10.3389/fmicb.2019.02150. eCollection 2019.

Regulated RNA turnover is vital for the control of gene expression in all cellular life. In

Cite
Mu R, Shinde P, Zou Z, et al. Examining the Protein Interactome and Subcellular Localization of RNase J2 Complexes in . Front Microbiol. 2019;10:2150doi: 10.3389/fmicb.2019.02150.
Mu, R., Shinde, P., Zou, Z., Kreth, J., & Merritt, J. (2019). Examining the Protein Interactome and Subcellular Localization of RNase J2 Complexes in . Frontiers in microbiology, 102150. https://doi.org/10.3389/fmicb.2019.02150
Mu, Rong, et al. "Examining the Protein Interactome and Subcellular Localization of RNase J2 Complexes in ." Frontiers in microbiology vol. 10 (2019): 2150. doi: https://doi.org/10.3389/fmicb.2019.02150
Mu R, Shinde P, Zou Z, Kreth J, Merritt J. Examining the Protein Interactome and Subcellular Localization of RNase J2 Complexes in . Front Microbiol. 2019 Sep 18;10:2150. doi: 10.3389/fmicb.2019.02150. eCollection 2019. PMID: 31620106; PMCID: PMC6759994.
Copy Download .nbib Format: NLM
Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer.

Cureus

Turina CB, Coleman DJ, Thomas GV, Fung AW, Alumkal JJ.
PMID: 31565603
Cureus. 2019 Jul 22;11(7):e5197. doi: 10.7759/cureus.5197.

Nearly all prostate cancers start out as adenocarcinomas driven by the androgen receptor (AR). Neuroendocrine prostate cancer (NEPC) is a rare, AR-independent subtype with a poor prognosis and limited treatment options. Importantly, because of the widespread use of novel...

Cite
Turina CB, Coleman DJ, Thomas GV, et al. Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer. Cureus. 2019;11(7):e5197doi: 10.7759/cureus.5197.
Turina, C. B., Coleman, D. J., Thomas, G. V., Fung, A. W., & Alumkal, J. J. (2019). Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer. Cureus, 11(7), e5197. https://doi.org/10.7759/cureus.5197
Turina, Claire B, et al. "Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer." Cureus vol. 11,7 (2019): e5197. doi: https://doi.org/10.7759/cureus.5197
Turina CB, Coleman DJ, Thomas GV, Fung AW, Alumkal JJ. Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer. Cureus. 2019 Jul 22;11(7):e5197. doi: 10.7759/cureus.5197. PMID: 31565603; PMCID: PMC6758987.
Copy Download .nbib Format: NLM
AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with .

Molecular cancer research : MCR

Haber AO, Jain A, Mani C, Nevler A, Agostini LC, Golan T, Palle K, Yeo CJ, Gmeiner WH, Brody JR.
PMID: 33593942
Mol Cancer Res. 2021 Apr;19(4):565-572. doi: 10.1158/1541-7786.MCR-20-0985. Epub 2021 Feb 16.

AraC-FdUMP[10] (CF10) is a second-generation polymeric fluoropyrimidine that targets both thymidylate synthase (TS), the target of 5-fluorouracil (5-FU), and DNA topoisomerase 1 (Top1), the target of irinotecan, two drugs that are key components of FOLFIRNOX, a standard-of-care regimen for...

Cite
Haber AO, Jain A, Mani C, et al. AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with . Mol Cancer Res. 2021;19(4):565-572doi: 10.1158/1541-7786.MCR-20-0985.
Haber, A. O., Jain, A., Mani, C., Nevler, A., Agostini, L. C., Golan, T., Palle, K., Yeo, C. J., Gmeiner, W. H., & Brody, J. R. (2021). AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with . Molecular cancer research : MCR, 19(4), 565-572. https://doi.org/10.1158/1541-7786.MCR-20-0985
Haber, Alex O, et al. "AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with ." Molecular cancer research : MCR vol. 19,4 (2021): 565-572. doi: https://doi.org/10.1158/1541-7786.MCR-20-0985
Haber AO, Jain A, Mani C, Nevler A, Agostini LC, Golan T, Palle K, Yeo CJ, Gmeiner WH, Brody JR. AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with . Mol Cancer Res. 2021 Apr;19(4):565-572. doi: 10.1158/1541-7786.MCR-20-0985. Epub 2021 Feb 16. PMID: 33593942.
Copy Download .nbib Format: NLM
Characterization of weaning-induced breast involution in women: implications for young women's breast cancer.

NPJ breast cancer

Jindal S, Narasimhan J, Borges VF, Schedin P.
PMID: 33083533
NPJ Breast Cancer. 2020 Oct 16;6:55. doi: 10.1038/s41523-020-00196-3. eCollection 2020.

In rodents, weaning-induced mammary gland involution supports increased mammary tumor incidence, growth, and progression to metastasis. Further, the protumor attributes of gland involution are COX-2 dependent and mitigated by short-duration non-steroidal anti-inflammatory drugs (NSAIDs), suggesting a potential prevention strategy....

Cite
Jindal S, Narasimhan J, Borges VF, et al. Characterization of weaning-induced breast involution in women: implications for young women's breast cancer. NPJ Breast Cancer. 2020;6:55doi: 10.1038/s41523-020-00196-3.
Jindal, S., Narasimhan, J., Borges, V. F., & Schedin, P. (2020). Characterization of weaning-induced breast involution in women: implications for young women's breast cancer. NPJ breast cancer, 655. https://doi.org/10.1038/s41523-020-00196-3
Jindal, Sonali, et al. "Characterization of weaning-induced breast involution in women: implications for young women's breast cancer." NPJ breast cancer vol. 6 (2020): 55. doi: https://doi.org/10.1038/s41523-020-00196-3
Jindal S, Narasimhan J, Borges VF, Schedin P. Characterization of weaning-induced breast involution in women: implications for young women's breast cancer. NPJ Breast Cancer. 2020 Oct 16;6:55. doi: 10.1038/s41523-020-00196-3. eCollection 2020. PMID: 33083533; PMCID: PMC7568540.
Copy Download .nbib Format: NLM
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma.

Cancer cell

Marin-Bejar O, Rogiers A, Dewaele M, Femel J, Karras P, Pozniak J, Bervoets G, Van Raemdonck N, Pedri D, Swings T, Demeulemeester J, Borght SV, Lehnert S, Bosisio F, van den Oord JJ, Bempt IV, Lambrechts D, Voet T, Bechter O, Rizos H, Levesque MP, Leucci E, Lund AW, Rambow F, Marine JC.
PMID: 34143978
Cancer Cell. 2021 Aug 09;39(8):1135-1149.e8. doi: 10.1016/j.ccell.2021.05.015. Epub 2021 Jun 17.

Therapy resistance arises from heterogeneous drug-tolerant persister cells or minimal residual disease (MRD) through genetic and nongenetic mechanisms. A key question is whether specific molecular features of the MRD ecosystem determine which of these two distinct trajectories will eventually...

Cite
Marin-Bejar O, Rogiers A, Dewaele M, et al. Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. Cancer Cell. 2021;39(8):1135-1149.e8doi: 10.1016/j.ccell.2021.05.015.
Marin-Bejar, O., Rogiers, A., Dewaele, M., Femel, J., Karras, P., Pozniak, J., Bervoets, G., Van Raemdonck, N., Pedri, D., Swings, T., Demeulemeester, J., Borght, S. V., Lehnert, S., Bosisio, F., van den Oord, J. J., Bempt, I. V., Lambrechts, D., Voet, T., Bechter, O., Rizos, H., Levesque, M. P., Leucci, E., Lund, A. W., Rambow, F., & Marine, J. C. (2021). Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. Cancer cell, 39(8), 1135-1149.e8. https://doi.org/10.1016/j.ccell.2021.05.015
Marin-Bejar, Oskar, et al. "Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma." Cancer cell vol. 39,8 (2021): 1135-1149.e8. doi: https://doi.org/10.1016/j.ccell.2021.05.015
Marin-Bejar O, Rogiers A, Dewaele M, Femel J, Karras P, Pozniak J, Bervoets G, Van Raemdonck N, Pedri D, Swings T, Demeulemeester J, Borght SV, Lehnert S, Bosisio F, van den Oord JJ, Bempt IV, Lambrechts D, Voet T, Bechter O, Rizos H, Levesque MP, Leucci E, Lund AW, Rambow F, Marine JC. Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. Cancer Cell. 2021 Aug 09;39(8):1135-1149.e8. doi: 10.1016/j.ccell.2021.05.015. Epub 2021 Jun 17. PMID: 34143978.
Copy Download .nbib Format: NLM
Comparing endocervical mucus proteome of humans and rhesus macaques.

Proteomics. Clinical applications

Han L, Park D, Reddy A, Wilmarth PA, Jensen JT.
PMID: 33991406
Proteomics Clin Appl. 2021 Jul;15(4):e2100023. doi: 10.1002/prca.202100023. Epub 2021 May 26.

PURPOSE: Endocervical mucus changes play a key role in regulating fertility throughout the menstrual cycle and in response to hormonal contraceptives. Non-human primates (NHP) provide the most translational animal model for reproductive tract studies, as they have hormonally-regulated menstrual...

Cite
Han L, Park D, Reddy A, et al. Comparing endocervical mucus proteome of humans and rhesus macaques. Proteomics Clin Appl. 2021;15(4):e2100023doi: 10.1002/prca.202100023.
Han, L., Park, D., Reddy, A., Wilmarth, P. A., & Jensen, J. T. (2021). Comparing endocervical mucus proteome of humans and rhesus macaques. Proteomics. Clinical applications, 15(4), e2100023. https://doi.org/10.1002/prca.202100023
Han, Leo, et al. "Comparing endocervical mucus proteome of humans and rhesus macaques." Proteomics. Clinical applications vol. 15,4 (2021): e2100023. doi: https://doi.org/10.1002/prca.202100023
Han L, Park D, Reddy A, Wilmarth PA, Jensen JT. Comparing endocervical mucus proteome of humans and rhesus macaques. Proteomics Clin Appl. 2021 Jul;15(4):e2100023. doi: 10.1002/prca.202100023. Epub 2021 May 26. PMID: 33991406; PMCID: PMC8653767.
Copy Download .nbib Format: NLM
Digesting the Importance of Cell Fusion in the Intestine.

Cellular and molecular gastroenterology and hepatology

Sutton TL, Walker BS, Wong MH.
PMID: 33068773
Cell Mol Gastroenterol Hepatol. 2021;11(1):299-302. doi: 10.1016/j.jcmgh.2020.07.013. Epub 2020 Oct 14.

No abstract available.

Cite
Sutton TL, Walker BS, Wong MH. Digesting the Importance of Cell Fusion in the Intestine. Cell Mol Gastroenterol Hepatol. 2020;11(1):299-302doi: 10.1016/j.jcmgh.2020.07.013.
Sutton, T. L., Walker, B. S., & Wong, M. H. (2021). Digesting the Importance of Cell Fusion in the Intestine. Cellular and molecular gastroenterology and hepatology, 11(1), 299-302. https://doi.org/10.1016/j.jcmgh.2020.07.013
Sutton, Thomas L, et al. "Digesting the Importance of Cell Fusion in the Intestine." Cellular and molecular gastroenterology and hepatology vol. 11,1 (2021): 299-302. doi: https://doi.org/10.1016/j.jcmgh.2020.07.013
Sutton TL, Walker BS, Wong MH. Digesting the Importance of Cell Fusion in the Intestine. Cell Mol Gastroenterol Hepatol. 2021;11(1):299-302. doi: 10.1016/j.jcmgh.2020.07.013. Epub 2020 Oct 14. PMID: 33068773; PMCID: PMC7768557.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 49 entries